Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Pursuing Diverse Applications for DehydraTECH™ Licensing

• Lexaria will license in any of the 40 countries where its technology already has a patent or is patent-pending
• Company sees up to 80 percent of its future revenues coming from licensing DehydraTECH proprietary ingestion delivery technology
• DehydraTECH™ has applications for processed foods, tobacco industry, pharmaceutical companies, NSAIDs, supplements and beverages

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has a wide variety of licensing applications for its patented DehydraTECH™ delivery technology. It is already licensed to Nuka Enterprises LLC, maker of “1906” brand cannabis chocolates (http://ibn.fm/lF00P). Chris Bunka, CEO, emphasizes that his company’s technology applies to far more than just the cannabis industry (http://ibn.fm/9AxYl), with the company indicating that it is also applicable to nicotine, NSAIDs, beverages, drugs and vitamins. LXRP forecasts that up to 80 percent of its total revenue could stem from licensing deals, the CEO added in a podcast interview with Uptick Newswire (http://ibn.fm/UK6y5).

Based in British Columbia, Canada, LXRP is a biotechnology company that out-licenses its disruptive delivery technology that promotes healthier ingestion methods. It results in lower dosing and higher effectiveness. LXRP holds a patent for oral delivery of all cannabinoids.

Its licenses are offered based upon geography, applications and product categories. LXRP’s patent portfolio protects its IP and is expanding. Last year, LXRP received its first U.S. patent on nicotine, ibuprofen and aspirin delivery, as well as cannabinoids. Bunka added that Lexaria’s technology is also in the active investigation phase in the EU, Canada, China, Japan and India.

The company’s patented DehydraTECH™ is key to LXRP’s valuation. The technology is being tested in human clinical studies for the delivery of cannabinoids through ingestible means. Results thus far have shown increased absorption rates with reduced time to enter the bloodstream and reported improvements in the taste and smell of edible products.

Lab tests on mice have shown a 50 percent improvement in active ingredients, such as nicotine, being absorbed into the bloodstream. They demonstrated even higher percentage levels absorbed into the brain. Bunka said that these results could potentially have an important impact on future treatment of cancer and brain tumors.

For more information, visit the company’s website at www.LexariaBioscience.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php